Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep 24;79(1):108–113. doi: 10.1038/sj.bjc.6690019

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

J van Asperen 1, O van Tellingen 1, F Tijssen 1, A H Schinkel 2, J H Beijnen 1,3
PMCID: PMC2362153  PMID: 10408701

Abstract

To gain more insight into the pharmacological role of endogenous P-glycoprotein in the metabolism of the widely used substrate drug doxorubicin, we have studied the plasma pharmacokinetics, tissue distribution and excretion of this compound in mdr1a(–/– and wild-type mice. Doxorubicin was administered as an i.v. bolus injection at a dose level of 5 mg kg−1. Drug and metabolite concentrations were determined in plasma, tissues, urine and faeces by high-performance liquid chromatography. In comparison with wild-type mice, the terminal half-life and the area under the plasma concentration–time curve of doxorubicin in it>mdr1a(–/–) mice were 1.6- and 1.2-fold higher respectively.The retention of both doxorubicin and its metabolite doxorubicinol in the hearts of mdr1a(–/–) mice was substantially prolonged. In addition, a significantly increased drug accumulation was observed in the brain and the liver of mdr1a(–/–) mice. The relative accumulation in most other tissues was not or only slightly increased. The differences in cumulative faecal and urinary excretion of doxorubicin and metabolites between both types of mice were small. These experiments demonstrate that the absence of mdr1a P-glycoprotein only slightly alters the plasma pharmacokinetics of oxorubicin. Furthermore, the substantially prolonged presence of both doxorubicin and doxorubicinol in cardiac tissue of mdr1a(–/–) mice suggests that a blockade of endogenous P-glycoprotein in patients, for example by a reversal agent, may enhance the risk of cardiotoxicity upon administration of doxorubicin. © 1999 Cancer Research Campaign

Keywords: P-glycoprotein, doxorubicin, reversal agents, cardiotoxicity, pharmacokinetics

Full Text

The Full Text of this article is available as a PDF (55.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett N. L., Lum B. L., Fisher G. A., Brophy N. A., Ehsan M. N., Halsey J., Sikic B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994 Apr;12(4):835–842. doi: 10.1200/JCO.1994.12.4.835. [DOI] [PubMed] [Google Scholar]
  2. Bellamy W. T., Peng Y. M., Odeleye A., Ellsworth L., Xu M. J., Grogan T. M., Weinstein R. S. Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anticancer Drugs. 1995 Dec;6(6):736–743. doi: 10.1097/00001813-199512000-00004. [DOI] [PubMed] [Google Scholar]
  3. Colombo T., Zucchetti M., D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther. 1994 Apr;269(1):22–27. [PubMed] [Google Scholar]
  4. Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989 Jan;86(2):695–698. doi: 10.1073/pnas.86.2.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Croop J. M., Raymond M., Haber D., Devault A., Arceci R. J., Gros P., Housman D. E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989 Mar;9(3):1346–1350. doi: 10.1128/mcb.9.3.1346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dantzig A. H., Shepard R. L., Cao J., Law K. L., Ehlhardt W. J., Baughman T. M., Bumol T. F., Starling J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56(18):4171–4179. [PubMed] [Google Scholar]
  7. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  8. Erlichman C., Moore M., Thiessen J. J., Kerr I. G., Walker S., Goodman P., Bjarnason G., DeAngelis C., Bunting P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 1993 Oct 15;53(20):4837–4842. [PubMed] [Google Scholar]
  9. Giaccone G., Linn S. C., Welink J., Catimel G., Stieltjes H., van der Vijgh W. J., Eeltink C., Vermorken J. B., Pinedo H. M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res. 1997 Nov;3(11):2005–2015. [PubMed] [Google Scholar]
  10. Gonzalez O., Colombo T., De Fusco M., Imperatori L., Zucchetti M., D'Incalci M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol. 1995;36(4):335–340. doi: 10.1007/BF00689051. [DOI] [PubMed] [Google Scholar]
  11. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993 Oct 1;53(19):4595–4602. [PubMed] [Google Scholar]
  12. Mayer U., Wagenaar E., Beijnen J. H., Smit J. W., Meijer D. K., van Asperen J., Borst P., Schinkel A. H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol. 1996 Nov;119(5):1038–1044. doi: 10.1111/j.1476-5381.1996.tb15775.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mayer U., Wagenaar E., Dorobek B., Beijnen J. H., Borst P., Schinkel A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997 Nov 15;100(10):2430–2436. doi: 10.1172/JCI119784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mross K., Maessen P., van der Vijgh W. J., Gall H., Boven E., Pinedo H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988 Mar;6(3):517–526. doi: 10.1200/JCO.1988.6.3.517. [DOI] [PubMed] [Google Scholar]
  15. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J., Jr Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 1988 May;85(10):3585–3589. doi: 10.1073/pnas.85.10.3585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schinkel A. H., Mayer U., Wagenaar E., Mol C. A., van Deemter L., Smit J. J., van der Valk M. A., Voordouw A. C., Spits H., van Tellingen O. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028–4033. doi: 10.1073/pnas.94.8.4028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994 May 20;77(4):491–502. doi: 10.1016/0092-8674(94)90212-7. [DOI] [PubMed] [Google Scholar]
  18. Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 Jun 1;97(11):2517–2524. doi: 10.1172/JCI118699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698–1705. doi: 10.1172/JCI118214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sparreboom A., van Asperen J., Mayer U., Schinkel A. H., Smit J. W., Meijer D. K., Borst P., Nooijen W. J., Beijnen J. H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031–2035. doi: 10.1073/pnas.94.5.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  23. Wacher V. J., Wu C. Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995 Jul;13(3):129–134. doi: 10.1002/mc.2940130302. [DOI] [PubMed] [Google Scholar]
  24. Webster L. K., Cosson E. J., Stokes K. H., Millward M. J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer. 1996 Feb;73(4):522–524. doi: 10.1038/bjc.1996.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. de Jong J., Schoofs P. R., Snabilié A. M., Bast A., van der Vijgh W. J. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther. 1993 Sep;266(3):1312–1320. [PubMed] [Google Scholar]
  26. van Asperen J., Schinkel A. H., Beijnen J. H., Nooijen W. J., Borst P., van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst. 1996 Jul 17;88(14):994–999. doi: 10.1093/jnci/88.14.994. [DOI] [PubMed] [Google Scholar]
  27. van Asperen J., van Tellingen O., Beijnen J. H. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 Aug 7;712(1-2):129–143. doi: 10.1016/s0378-4347(98)00165-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES